The law-firm wave is not the story - the story is revenue-quality doubt that can linger in small-cap healthcare
The Opportunity
This is an emerging cluster (rating D) capturing a familiar sequence: catalyst allegation, drawdown, then a burst of solicitation-style investigation releases. 7A is still directionally SHORT on a biotech proxy because even when the legal content is low-signal, the underlying catalyst (revenue quality, channel stuffing, backlog cancellation narratives) can keep investors sceptical and risk premia elevated across adjacent names. The edge is in recognising the persistence of the narrative rather than overfitting to any one law firm release.
The Timing
Freshness is 65 but staleness risk is flagged as possible reprint tied to a March 24, 2026 catalyst, which means this is late-stage distribution rather than first discovery. That does not invalidate the SHORT, but it does compress the timing edge: the next market-moving step needs to be a primary filing, an issuer disclosure, or a credible independent validation. In a Mixed 58 tape, this can fade quickly if no docket-level substance shows up, so the key conversion trigger is corroboration beyond PR distribution.
The Evidence
Hydrated evidence is dominated by distribution wires, including a GlobNewswire investigation item on ADMA Biologics tied to a Culper Research allegation set ( globenewswire.com ) and multiple class action style releases across other tickers in the cluster. 7A is explicit about what would promote: court dockets/complaints or issuer disclosures; and what would demote: evidence the whole cluster is solicitation without substance. That is the correct filter for whether this remains tradable or becomes noise.